Search Results - "Brichard, Vincent"

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy by ULLOA-MONTOYA, Fernando, LOUAHED, Jamila, BRICHARD, Vincent G, DIZIER, Benjamin, GRUSELLE, Olivier, SPIESSENS, Bart, LEHMANN, Frédéric F, SUCIU, Stefan, KRUIT, Wim H. J, EGGERMONT, Alexander M. M, VANSTEENKISTE, Johan

“…To detect a pretreatment gene expression signature (GS) predictive of response to MAGE-A3 immunotherapeutic in patients with metastatic melanoma and to…”
Get full text

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results by VANSTEENKISTE, Johan, ZIELINSKI, Marcin, PERDEUS, Jakub, BONNET, Reiner, BASKO, Jazeps, JANILIONIS, Richard, PASSLICK, Bernward, TREASURE, Tom, GILLET, Marc, LEHMANN, Frédéric F, BRICHARD, Vincent G, LINDER, Albert, DAHABREH, Jubrail, GONZALEZ, Emilio E, MALINOWSKI, Wojciech, LOPEZ-BREA, Marta, VANAKESA, Tonu, JASSEM, Jacek, KALOFONOS, Haralabos

“…The MAGE-A3 protein is expressed in approximately 35% of patients with resectable non-small-cell lung cancer (NSCLC). Several immunization approaches against…”
Get full text

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy by Gajewski, Thomas F, Louahed, Jamila, Brichard, Vincent G

“…Immunotherapeutic approaches for melanoma and other cancers can impart profound clinical benefit but only for a subset of patients. Interpatient heterogeneity…”
Get full text

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development by Brichard, Vincent G, Lejeune, Diane

“…Abstract From the first evidence that the immune system could recognize tumors, different types of tumor antigens have been identified and deeply…”
Get full text

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study by Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A, Shen, Robert, Tjulandin, Sergei A, Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F

“…Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially…”
Get more information

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial by Dreno, Brigitte, Thompson, John F, Smithers, Bernard Mark, Santinami, Mario, Jouary, Thomas, Gutzmer, Ralf, Levchenko, Evgeny, Rutkowski, Piotr, Grob, Jean-Jacques, Korovin, Sergii, Drucis, Kamil, Grange, Florent, Machet, Laurent, Hersey, Peter, Krajsova, Ivana, Testori, Alessandro, Conry, Robert, Guillot, Bernard, Kruit, Wim H J, Demidov, Lev, Thompson, John A, Bondarenko, Igor, Jaroszek, Jaroslaw, Puig, Susana, Cinat, Gabriela, Hauschild, Axel, Goeman, Jelle J, van Houwelingen, Hans C, Ulloa-Montoya, Fernando, Callegaro, Andrea, Dizier, Benjamin, Spiessens, Bart, Debois, Muriel, Brichard, Vincent G, Louahed, Jamila, Therasse, Patrick, Debruyne, Channa, Kirkwood, John M

“…Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic…”
Get full text

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma by KRUIT, Wim H. J, SUCIU, Stefan, BECKER, Juergen C, SPATZ, Alan, EGGERMONT, Alexander M. M, LOUAHED, Jamila, LEHMANN, Frédéric F, BRICHARD, Vincent G, KEILHOLZ, Ulrich, DRENO, Brigitte, MORTIER, Laurent, ROBERT, Caroline, CHIARION-SILENI, Vanna, MAIO, Michele, TESTORI, Alessandro, DORVAL, Thierry, GROB, Jean-Jacques

“…Active immunization against the tumor-specific MAGE-A3 antigen is followed by a few but impressive and durable clinical responses. This randomized phase II…”
Get full text

Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology by Michaud, Jean-Philippe, Hallé, Maxime, Lampron, Antoine, Thériault, Peter, Préfontaine, Paul, Filali, Mohammed, Tribout-Jover, Pascale, Lanteigne, Anne-Marie, Jodoin, Rachel, Cluff, Christopher, Brichard, Vincent, Palmantier, Rémi, Pilorget, Anthony, Larocque, Daniel, Rivest, Serge

“…Alzheimer’s disease (AD) is the most common cause of dementia worldwide. The pathogenesis of this neurodegenerative disease, currently without curative…”
Get full text

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer by Pujol, Jean-Louis, Vansteenkiste, Johan F, De Pas, Tommaso Martino, Atanackovic, Djordje, Reck, Martin, Thomeer, Michiel, Douillard, Jean-Yves, Fasola, Gianpiero, Potter, Vanessa, Taylor, Paul, Bosquée, Lionel, Scheubel, Robert, Jarnjak, Silvija, Debois, Muriel, de Sousa Alves, Pedro, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F

“…To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive non-small-cell lung cancer (NSCLC) who were…”
Get more information

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer by Dizier, Benjamin, Callegaro, Andrea, Debois, Muriel, Dreno, Brigitte, Hersey, Peter, Gogas, Helen J, Kirkwood, John M, Vansteenkiste, Johan F, Sequist, Lecia V, Atanackovic, Djordje, Goeman, Jelle, van Houwelingen, Hans, Salceda, Susana, Wang, Fawn, Therasse, Patrick, Debruyne, Channa, Spiessens, Bart, Brichard, Vincent G, Louahed, Jamila, Ulloa-Montoya, Fernando

“…Immune components of the tumor microenvironment (TME) have been associated with disease outcome. We prospectively evaluated the association of an…”
Get full text

Expression of tumor-associated antigens in breast cancer subtypes by Curigliano, Giuseppe, Bagnardi, Vincenzo, Ghioni, Mariacristina, Louahed, Jamila, Brichard, Vincent, Lehmann, Frederic F., Marra, Antonio, Trapani, Dario, Criscitiello, Carmen, Viale, Giuseppe

“…Tumor-associated antigens (TAAs) are frequently overexpressed in several cancer types. The aim of this study was to investigate the expression of TAAs in…”
Get full text

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease by Brichard, Vincent G, Lejeune, Diane

“…Clinical investigation of cancer immunotherapy has been very active and several approaches have been evaluated in Phase III trials. In particular, the…”
Get more information

MAGE-A3-specific anticancer immunotherapy in the clinical practice by Brichard, Vincent G., Godechal, Quentin

“…Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant…”
Get full text

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients by Thongprasert, Sumitra, Yang, Pan-Chyr, MD, PhD, Lee, Jung Shin, Soo, Ross, Gruselle, Olivier, Myo, Aung, Louahed, Jamila, Lehmann, Frédéric F, Brichard, Vincent G, Coche, Thierry

“…Highlights • MAGE-A3 and PRAME tumor antigen co-expressed in 20% of NSCLC tumors of Asian patients. • Higher rates of antigen-positive tumors in squamous cell…”
Get full text

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy by Brichard, Vincent G, Louahed, Jamila, Clay, Timothy M

Get full text

A Monoclonal Cytolytic T-Lymphocyte Response Observed in a Melanoma Patient Vaccinated with a Tumor-Specific Antigenic Peptide Encoded by Gene MAGE-3 by Coulie, Pierre G., Karanikas, Vaios, Colau, Didier, Lurquin, Christophe, Landry, Claire, Marchand, Marie, Dorval, Thierry, Brichard, Vincent, Boon, Thierry

“…Vaccination of melanoma patients with tumor-specific antigens recognized by cytolytic T lymphocytes (CTL) produces significant tumor regressions in a minority…”
Get full text

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma by Kruit, Wim H.J., van Ojik, Heidi H., Brichard, Vincent G., Escudier, Bernard, Dorval, Thierry, Dréno, Brigitte, Patel, Poulam, van Baren, Nicolas, Avril, Marie‐Françoise, Piperno, Sophie, Khammari, Amir, Stas, Marguerite, Ritter, Gerd, Lethé, Bernard, Godelaine, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, Alexander M.M., Marchand, Marie

“…The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a…”
Get full text

Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma by SZMANIA, Susann, GNJATIC, Sacha, OLD, Lloyd J, BARLOGIE, Bart, BRICHARD, Vincent G, VAN RHEE, Frits, TRICOT, Guido, STONE, Katie, FENGHUANG ZHAN, MORENO, Amberly, THURO, Brad, MELENHORST, Jos, BARRETT, John, SHAUGHNESSY, John

“…MAGE-A3 is frequently expressed in high-risk multiple myeloma (MM). We immunized a healthy donor with MAGE-A3 protein formulated in AS02B to transfer immunity…”
Get full text

Immune Responses to a Class II Helper Peptide Epitope in Patients with Stage III/IV Resected Melanoma by WONG, Raymond, LAU, Roy, CHANG, Jenny, KUUS-REICHEL, Tina, BRICHARD, Vincent, BRUCK, Claudine, WEBER, Jeffrey

“…The importance of CD8 + cytolytic T cells for protection from viral infection and in the generation of immune responses against tumors has been well…”
Get full text

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells by VAN BAREN, Nicolas, BONNET, Marie-Claude, ESCUDIER, Bernard, NEGRIER, Sylvie, DIETRICH, Pierre-Yves, MARANINCHI, Dominique, OSANTO, Susanne, MEYER, Ralf G, RITTER, Gerd, MOINGEON, Philippe, TARTAGLIA, Jim, VAN DER BRUGGEN, Pierre, DRENO, Brigitte, COULIE, Pierre G, BOON, Thierry, KHAMMARI, Amir, DORVAL, Thierry, PIPERNO-NEUMANN, Sophie, LIENARD, Danielle, SPEISER, Daniel, MARCHAND, Marie, BRICHARD, Vincent G

“…To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus…”
Get full text